Decentralizing the Cure: The Road to Community-Based CAR-T скачать в хорошем качестве

Decentralizing the Cure: The Road to Community-Based CAR-T

In this episode, host Nico sits down with repeat guest Lee Buckler to tackle the "80/20" problem in cell and gene therapy: the fact that while 80% of patients are treated in community settings, CAR-T therapies are currently stuck in high-level academic centers. We explore the history of patient access from the stem cell transplant model to the lessons learned from Dendreon’s Provenge and map out the infrastructure needed to bring these cures to the local level. From the "10-mile rule" of patient attrition to the massive financial hurdles of carrying multi-million dollar therapies on a hospital’s books, this conversation digs into the operational reality of scaling life-saving science Key Discussion Points The 10-Mile Rule: Why every 10 miles of distance from a treatment center results in a 6.2% drop in the likelihood of a patient receiving CAR-T. Infrastructure vs. Business Hurdles: Analyzing why the $500,000 to $3 million upfront cost of therapy creates massive cash-flow barriers for community hospitals. Decentralizing the "Vein-to-Vein" Process: How Blood Centers of America (BCA) and FACT are establishing new standards for local apheresis and infusion. Safety and Remote Monitoring: How wearable tech and reduced FDA REMS requirements are allowing patients to recover at home sooner. The Future of Cost: A look at how non-profit models and 5-year ROI data are shifting the payer landscape. Show Notes 00:21 – The dual history of cell therapy: Stem cell transplants vs. Provenge. 05:43 – The community access gap: Why CAR-T sales have plateaued at 20%. 11:48 – Expanding into autoimmune: Why local delivery is no longer optional. 19:30 – Logistics and Cryopreservation: Building a national infrastructure. 34:33 – Financial bottlenecks and the reality of reimbursement. 51:41 – Advancements in remote monitoring and patient safety. 58:48 – Insurance, ROI, and the rise of generic models.